Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice

Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of... Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with high-cardiovascular risk and significant morbidity and mortality. The recent development of sodium-glucose cotransporter (SGLT) 2 inhibitors offers a new antidiabetic therapy via enhanced glucose excretion; however, the beneficial effect of these drugs on the development of type 2 diabetic overt nephropathy is still largely unclear. We examined the therapeutic effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and the progression of nephropathy in uninephrectomized type 2 diabetic mice, which exhibit not only typical diabetic symptoms, such as impaired insulin secretion, glucose intolerance, hyperglycemia, and obesity, but also overt nephropathy with decline in renal function. Diabetes was induced by intraperitoneal administration of nicotinamide (1000 mg/kg) and streptozotocin (150 mg/kg) to uninephrectomized high-fat diet-fed mice. Ipragliflozin (0.1–3 mg/kg) was orally administered to diabetic mice once daily for 4 weeks. Repeated administration of ipragliflozin improved diabetic symptoms, such as hyperglycemia and insulin resistance, via an increase in urinary glucose excretion. In addition, ipragliflozin attenuated albuminuria/proteinuria and the decline in renal function, and improved renal injury, including glomerulosclerosis and interstitial fibrosis. Our results demonstrate that ipragliflozin improves various diabetic symptoms and delays development of diabetic nephropathy. Therefore, SGLT2 inhibitors could constitute a novel therapeutic target for the treatment of type 2 diabetes with overt nephropathy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Naunyn-Schmiedeberg's Archives of Pharmacology Springer Journals

Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice

Loading next page...
 
/lp/springer_journal/effects-of-the-sglt2-inhibitor-ipragliflozin-on-various-diabetic-iWUAKUeU27
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology; Neurosciences
ISSN
0028-1298
eISSN
1432-1912
D.O.I.
10.1007/s00210-018-1469-5
Publisher site
See Article on Publisher Site

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with high-cardiovascular risk and significant morbidity and mortality. The recent development of sodium-glucose cotransporter (SGLT) 2 inhibitors offers a new antidiabetic therapy via enhanced glucose excretion; however, the beneficial effect of these drugs on the development of type 2 diabetic overt nephropathy is still largely unclear. We examined the therapeutic effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and the progression of nephropathy in uninephrectomized type 2 diabetic mice, which exhibit not only typical diabetic symptoms, such as impaired insulin secretion, glucose intolerance, hyperglycemia, and obesity, but also overt nephropathy with decline in renal function. Diabetes was induced by intraperitoneal administration of nicotinamide (1000 mg/kg) and streptozotocin (150 mg/kg) to uninephrectomized high-fat diet-fed mice. Ipragliflozin (0.1–3 mg/kg) was orally administered to diabetic mice once daily for 4 weeks. Repeated administration of ipragliflozin improved diabetic symptoms, such as hyperglycemia and insulin resistance, via an increase in urinary glucose excretion. In addition, ipragliflozin attenuated albuminuria/proteinuria and the decline in renal function, and improved renal injury, including glomerulosclerosis and interstitial fibrosis. Our results demonstrate that ipragliflozin improves various diabetic symptoms and delays development of diabetic nephropathy. Therefore, SGLT2 inhibitors could constitute a novel therapeutic target for the treatment of type 2 diabetes with overt nephropathy.

Journal

Naunyn-Schmiedeberg's Archives of PharmacologySpringer Journals

Published: Jan 26, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial